Companies
Geneseeq Technology
participates in China's precision-oncology genomic testing market as part of the country's growing domestic multi-omic testing base.
- Country
- China
Growth
Precision-oncology genomic testing
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Capacity | High-throughput sequencing capacity with 310,000+ clinical samples processed to date | na.geneseeq.com |
| Certification | CAP, CLIA, ISO 15189, and ISO 13485 certifications for laboratories and manufacturing facilities | biobase.whitefordresearch.com · na.geneseeq.com |
| Regulatory approval | Multiple NMPA approvals in China for diagnostic kits including PanTRKare and large-panel NGS assays, as well as U.S. FDA clearances and CE-IVD markings for various assays | na.geneseeq.com · prnewswire.com · vcbeathealth.com |
| Production site | Core laboratories in Nanjing, Shanghai, Beijing, and Guangzhou; manufacturing facility in Nanjing | biobase.whitefordresearch.com · prnewswire.com |
| Headcount | 339 employees reported in 2025 annual report; other reports estimate over 1,500 professionals (2025-12-31) medium confidence | qiye.qizhidao.com · investnj.org.cn |
| Revenue | RMB 577 million for full-year 2025 (2025-12-31) | qiye.qizhidao.com · vcbeathealth.com |
Independent sources: biobase.whitefordresearch.com · investnj.org.cn · na.geneseeq.com · prnewswire.com · qiye.qizhidao.com · vcbeathealth.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Multi-omics diagnostic panels for precision oncology | diagnostics-medtech | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.